close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BioSkryb Genomics

News headline image
BioSkryb Genomics Launches ResolveSEQ LongRead Early Access Program for Powerful Single-Cell Long-Read Sequencing
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Secures Exclusive License to Breakthrough Methylation Patent to Enable the First Single-Cell Five-Base Genome
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics and Ultima Genomics Launch Collaborative Grant Program to Advance Oncology Research
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Partners with the Human Cell Atlas to Advance Access to the Next Generation of Single-Cell Technology
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics to Highlight Power of Next Generation Single-Cell Technology at AGBT 2024
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics to Present New Single-Cell Multiomic Data at ASHG 2023
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Joins NIST Genome Editing Consortium to Define Standards in Genome Editing Research and Commercialization
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Partners with Research Instruments Pte Ltd to Bring Industry Leading Single-Cell Technologies to Singapore and Southeast Asia
From BioSkryb Genomics
Via Business Wire
News headline image
Patent Awarded for Primary Template-Directed Amplification, Further Strengthening BioSkryb Genomics’ Core Technologies
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics to Bring High-Throughput Automation to Single-Cell Genomics
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Unveils New Research Findings Related to Breast Cancer Tumor Evolution
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Announces Commercial Launch of ResolveOME System and BaseJumper Bioinformatics Platform
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Welcomes Accomplished Genomics Executive Suresh Pisharody as New CEO
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics and Cooper Surgical Ink Multi-Year Deal to Accelerate Clinical Discovery and Diagnostics in Women’s Reproductive Health
From BioSkryb Genomics
Via Business Wire
News headline image
BioXpedia A/S and BioSkryb Genomics Announce European Partnership to Provide Groundbreaking, Single-Cell, Multiomic Analysis for Novel Target Identification and Therapeutic Development
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics Launches ResolveOME Early Access Program for Full Genome and Transcriptome Amplification From a Single Cell, in Conjunction With Its Innovative Bioinformatics Platform, BaseJumper™
From BioSkryb Genomics
Via Business Wire
News headline image
BioSkryb Genomics and ALS Automated Lab Solutions GmbH Sign U.S. Distribution Agreement to Power Unprecedented Single Cell Spatial Genomics
From BioSkryb Genomics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today